Opinion|Videos|August 4, 2026

How Does Solriamfetol's DNRI Mechanism Differ From Other Wakefulness Agents?

Winter explains solriamfetol's distinct pharmacological profile as a dopamine-norepinephrine reuptake inhibitor—the first and only agent in its class approved specifically for EDS—and discusses why this mechanism matters clinically compared to other available wakefulness-promoting options.

Winter explains solriamfetol's distinct pharmacological profile as a dopamine-norepinephrine reuptake inhibitor—the first and only agent in its class approved specifically for EDS—and discusses why this mechanism matters clinically compared to other available wakefulness-promoting options.


Latest CME